Author

C. Hamor

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Y. Gao· 3 shared C. Perou· 2 shared D. Pedroza· 2 shared J. M. Rosen· 2 shared A. Malovannaya· 1 shared A. Saltzman· 1 shared A. Smith· 1 shared B. Zhang· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Y. Gao

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer

N. Zhao, E. Kabotyanski, A. Saltzman, A. Malovannaya, X. Yuan, L. Reineke, N. Lieu, Y. Gao, D. Pedroza, S. Calderon, A. Smith, C. Hamor, K. Safari, S. Savage, B. Zhang, , J. Rosen

Zotatifin targets EIF4A to suppress TNBC by inhibiting Sox4, inducing interferon response, and reprogramming the tumor immune microenvironment, synergizing with chemotherapy.

bioRxiv · Sep 28, 2023Cancer Biology

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics

Y. Gao, E. B. Kabotyanski, E. Villegas, J. H. Shepherd, D. Acosta, C. Hamor, T. Sun, C. Montemayor-Garcia, X. He, L. E. Dobrolecki, T. F. Westbrook, M. T. Lewis, S. G. Hilsenbeck, X. H.- F. Zhang, C. M. Perou, J. M. Rosen

This study shows PLK2 loss predicts better response to PLK1 inhibitors in triple-negative breast cancer and suggests PLK2 as a biomarker for treatment response.

bioRxiv · Jun 16, 2021Cancer Biology

Chemotherapy coupled to macrophage inhibition leads to enhanced T and B cell infiltration and durable triple negative breast cancer regression

S. Singh, N. Lee, D. Pedroza, I. Bado, C. Hamor, L. Zhang, S. Aguirre, J. Hu, Y. Shen, Y. Xu, Y. Gao, N. Zhan, S.-H. Chen, Y.-W. Wan, Z. Liu, , J. M. Rosen

bioRxiv · Feb 22, 2021 · PreprintCancer Biology